Pharmaceutical Mail. Doctors and pharmacists agree that protocols should be established on when to opt for one brand or another. The patients naive They would be the natural scenario for the biosimilar and they see no point in changing established therapies.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
